Is Alivus Life Sciences the Best Stock in Its Sector? A Look at the Numbers
- September 18, 2026
- Posted by: Harsh Piplani
- Category: Market
Alivus Life Sciences CMP Rs 1,388 (18 Sep 2026). Market cap Rs 17,029 Cr. ROE 16.94%. P/E 28.24x versus Industry P/E 50.18x.
Quick Answer
Alivus Life Sciences is one of the names investors compare when screening the Healthcare sector, built on a 16.94% return on equity and a P/E of 28.24x against an Industry P/E of 50.18x. Whether Alivus Life Sciences is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.
Is Alivus Life Sciences the best stock in its sector? The stock trades on the NSE at Rs 1,388 as of 18 September 2026, within its 52-week range of Rs 819.00 to Rs 1,493.80. Alivus Life Sciences Ltd, formerly Glenmark Life Sciences, manufactures active pharmaceutical ingredients for global pharmaceutical customers.
Alivus Life Sciences sits in the Healthcare sector, and its 16.94% ROE and 28.24x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Alivus Life Sciences
Alivus Life Sciences Ltd, formerly Glenmark Life Sciences, manufactures active pharmaceutical ingredients for global pharmaceutical customers. It was renamed from Glenmark Life Sciences after the Nirma Group acquired a majority stake, and manufactures active pharmaceutical ingredients for global pharma customers. At a market capitalisation of Rs 17,029 Cr, it is tracked as part of the Healthcare sector on Univest.
Is Alivus Life Sciences the Best Stock in Its Sector?
Alivus Life Sciences makes its case as the best stock in its sector primarily on return on equity and balance sheet strength, combining a 16.94% ROE with a 28.24x P/E against the sector’s 50.18x Industry P/E. Alivus Life Sciences’ 28.24x P/E is well below the 50.18x Industry P/E despite a 16.94% ROE ahead of Akums Drugs and Pharmaceuticals in this comparison, making it look inexpensive relative to its own quality among the CDMO and API peers covered in this series.
| Metric | Alivus Life Sciences |
|---|---|
| CMP (NSE) | Rs 1,387.80 |
| 52-Week High / Low | Rs 1,493.80 / Rs 819.00 |
| Market Cap | Rs 17,029 Cr |
| P/E (TTM) vs Industry P/E | 28.24x vs 50.18x |
| P/B | 5.11 |
| ROE | 16.94% |
| EPS (TTM) | Rs 49.12 |
| Dividend Yield | 0.36% |
| Debt to Equity | 0.02 |
Compare Alivus Life Sciences Against Other Healthcare Sector Stocks
How Alivus Life Sciences Compares Against Its Healthcare Sector Peers
The table below sets Alivus Life Sciences against 3 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 3 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Alivus Life Sciences | 17,029 | 28.24 | 16.94% | 0.02 |
| Akums Drugs and Pharmaceuticals | 12,059 | 41.19 | 7.70% | 0.05 |
| Sai Life Sciences | 32,723 | 90.47 | 14.05% | 0.12 |
| Gland Pharma | 48,215 | 42.71 | 9.92% | 0.03 |
| Peer average (3 companies) | – | 58.12 | 10.56% | 0.07 |
Against this peer set, Alivus Life Sciences’s 16.94% ROE is above the 10.56% peer average, and its P/E of 28.24x runs below the peer average of 58.12x. Alivus Life Sciences’ 28.24x P/E is well below the 50.18x Industry P/E despite a 16.94% ROE ahead of Akums Drugs and Pharmaceuticals in this comparison, making it look inexpensive relative to its own quality among the CDMO and API peers covered in this series.
What Makes Alivus Life Sciences Worth Watching in Healthcare
- Well below Industry P/E: A 28.24x P/E against a 50.18x Industry P/E is a significant discount for an API manufacturer with a 16.94% ROE.
- Near debt free: A debt to equity ratio of 0.02 gives Alivus Life Sciences flexibility to invest in manufacturing capacity.
- Global API manufacturing scale: Manufacturing active pharmaceutical ingredients for global pharma customers gives Alivus Life Sciences a diversified, export-oriented customer base.
Alivus Life Sciences Valuation: Is It Justified?
Alivus Life Sciences’ 28.24x P/E is well below the 50.18x Industry P/E despite a 16.94% ROE ahead of Akums Drugs and Pharmaceuticals in this comparison, making it look inexpensive relative to its own quality among the CDMO and API peers covered in this series. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is Aditya Birla Lifestyle Brands the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Alivus Life Sciences and other Healthcare sector stocks.
How to Track Alivus Life Sciences Before You Invest
Before deciding whether Alivus Life Sciences deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.
- Open the Univest Screener and search for Alivus Life Sciences to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
- Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Alivus Life Sciences earns a place in the best stock in its sector conversation on the strength of a 16.94% ROE and a P/E of 28.24x against a 50.18x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Alivus Life Sciences the best stock in its sector?
Ans. Alivus Life Sciences has a 16.94% ROE and trades at 28.24x P/E against a 50.18x Industry P/E, and compares above the peer average ROE of 10.56% in this article’s named comparison, so the answer depends on what an investor is prioritising.
What is the current share price of Alivus Life Sciences?
Ans. Alivus Life Sciences was trading at Rs 1,387.80 on the NSE as of 18 September 2026, within its 52-week range of Rs 819.00 to Rs 1,493.80.
What sector does Alivus Life Sciences belong to?
Ans. Alivus Life Sciences is classified under the Healthcare sector on Univest.
How does Alivus Life Sciences compare to its sector peers on P/E?
Ans. Alivus Life Sciences’s P/E of 28.24x is below the 58.12x average of the 3 named peers compared in this article.
What is Alivus Life Sciences’s return on equity?
Ans. Alivus Life Sciences reported a return on equity of 16.94%, which is above the 10.56% average of its named peers in this comparison.
Should I invest in Alivus Life Sciences based on its sector position?
Ans. Alivus Life Sciences’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.
